What is the current recommended management of acute intracerebral hemorrhage?

Current Management of Acute Intracerebral Hemorrhage

For patients with acute ICH presenting with systolic blood pressure (SBP) 150-220 mmHg and mild-to-moderate severity (GCS ≥5), lower SBP to a target of 130-140 mmHg as rapidly as possible, but avoid dropping below 130 mmHg as this is potentially harmful. 1

Blood Pressure Management

Target Range and Timing

• Initiate blood pressure lowering immediately upon presentation for patients with SBP between 150-220 mmHg, targeting 130-140 mmHg 1
• Begin treatment within 2 hours of symptom onset when possible, as earlier intervention (within 2 hours) is associated with reduced hematoma expansion and improved 90-day outcomes compared to later treatment 1
• Critical safety threshold: Do NOT lower SBP below 130 mmHg in patients with moderate severity ICH, as acute lowering to <130 mmHg is potentially harmful 1

Blood Pressure Control Strategy

• Achieve smooth, sustained BP control with minimal variability, as increased SBP variability during the first 24 hours has a linear association with death and severe disability at 90 days 1
• Use intravenous agents with rapid onset and short duration to facilitate easy titration (nicardipine is well-studied; avoid venous vasodilators due to potential harm from unopposed venodilation affecting hemostasis and intracranial pressure) 1
• Aim for SBP reductions ≥20 mmHg during the first hour after treatment initiation and maintain control for 7 days, as this is associated with lowest risks of death and major disability 1

Anticoagulation Reversal

Vitamin K Antagonists (Warfarin)

• Reverse immediately with prothrombin complex concentrate (PCC), as rapid reversal reduces hematoma expansion risk and may improve outcomes 2

Direct Oral Anticoagulants

• Dabigatran: Reverse with idarucizumab 2
• Anti-Xa agents (rivaroxaban, apixaban, edoxaban): Reverse with PCC or andexanet alfa where available 2

Hematoma Expansion Prevention

• Identify high-risk patients through radiological imaging to implement targeted strategies for stabilizing hematoma volume 3
• The window for preventing hematoma expansion extends through the period of high risk for further expansion, which is primarily within the first few hours after onset 1

Surgical Considerations

Indications for Neurosurgical Consultation

• Cerebellar hemorrhage with mass effect 3
• Intraventricular hemorrhage requiring external ventricular drainage for hydrocephalus 2
• Supratentorial ICH with significant mass effect 3
• Meta-analyses report increased likelihood of good functional outcome and lower risk of death with surgery compared to medical treatment alone, though no single large phase III trial has shown overall benefit 2

Emerging Surgical Approaches

• Minimally invasive techniques including endoport and endoscope-assisted evacuation are emerging as alternatives to traditional craniotomy 4

Critical Care Management

Unit-Based Care

• Admit all ICH patients to stroke units or neurological intensive care units with neurocritical care expertise, as this reduces mortality 5, 2
• Implement bundled care approaches incorporating all five key components: hematoma expansion prediction, blood pressure control, hemostasis, anticoagulation reversal, and surgical intervention where appropriate 3

Supportive Measures

• Seizure management: Treat clinical seizures promptly 6
• Metabolic control: Maintain normoglycemia and normothermia 6
• Intracranial pressure management: Monitor and treat elevated ICP in appropriate patients 7

Prognostication and Goals of Care

• Avoid early nihilism: Recent data underscore the protracted course of recovery after ICH, particularly in patients with severe disability 4
• Delay withdrawal decisions: Use early do-not-resuscitate orders or withdrawal of active care judiciously in the first 24-48 hours, as early prognostication is difficult 2

Common Pitfalls to Avoid

• Excessive BP lowering: Dropping SBP below 130 mmHg in moderate severity ICH is harmful 1
• Large BP fluctuations: Avoid reductions ≥60 mmHg within 1 hour, as this may worsen outcomes 2
• Delayed anticoagulation reversal: Any delay increases hematoma expansion risk 2
• Premature prognostication: Making withdrawal decisions in the first 24-48 hours may deny patients the opportunity for meaningful recovery 4, 2